Experimental Medicine Initiative to Explore New Therapies (EMINENT)
Accessing GSK's clinic ready portfolio to enable translational discovery
Bringing together investigators from University College London (Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø), the University of Cambridge, the University of Glasgow, the University of Newcastle, Imperial College London and GlaxoSmithKline (GSK), with unprecedented access to GSK's unlicenced clinic-ready asset portfolio to enable experimental medicine studies aimed at enhancing understanding of disease mechanisms and accelerating development of novel therapeutics for patients in under-served disease areas.